https://orcid.org/0000-0002-8673-2450
Citations (42)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Sofia Lampaki, Giannis Mountzios, Vassilis Georgoulias, Aggeliki Rapti, Ioannis Xanthakis, Sofia Baka, Dimitrios Mavroudis, Epaminondas Samantas, Elias Athanasiadis, Flora Zagouri, Andriani Charpidou, Alvertos Somarakis, Christina Papista, Aristeidis Nikolaou, Eleftheria Anastasopoulou, Zoe Paparepa & Konstantinos N Syrigos. (2022) Real-world Management Patterns in EGFR-mutant Advanced Non-Small-Cell Lung Cancer before First-Line Adoption of Osimertinib: The REFLECT Study in Greece. Future Oncology 18:28, pages 3151-3164.
Read now
Read now
Jun Zhao, Hua Bai, Xin Wang, Yuyan Wang, Jianchun Duan, Hanxiao Chen, Zhiyi Xue, Yahui Tian, Agnieszka Cseh, Dennis Chin-Lun Huang, Yi-Long Wu & Jie Wang. (2022) Biomarker Subset Analysis of a Phase IIIb, Open-Label Study of Afatinib in EGFR Tyrosine Kinase Inhibitor-Naive Patients with EGFRm+ Non-Small-Cell Lung Cancer. Future Oncology 18:12, pages 1485-1497.
Read now
Read now
Louis J Gautier & Lana Shkak. (2022) Past, Present and Future Oncology: Welcome to Volume 18. Future Oncology 18:1, pages 1-5.
Read now
Read now
Giannis Mountzios, Sofia Lampaki, Georgia-Angeliki Koliou, Athanassios Vozikis, Ioannis Kontogiorgos, Panagiotis Papantoniou, Margarita-Ioanna Koufaki, Eleni Res, Anastasios Boutis, Athina Christopoulou, Nicoleta Pastelli, Anastasios Grivas, Gerasimos Aravantinos, Efthalia Lalla, Georgios Oikonomopoulos, Anna Koumarianou, Dionisios Spyratos, Dimitrios Bafaloukos$suffix/text()$suffix/text(), Georgios Rigakos, Pavlos Papakotoulas, George Fountzilas & Helena Linardou. (2021) An Observational Study to Assess the Molecular Epidemiology and Direct Medical Costs of Epidermal Growth Factor Receptor (EGFR) Mutations in Patients with Advanced EGFR Mutation-Positive Non-Small Cell Lung Cancer Treated with Afatinib in Real-World Clinical Settings in Greece. Lung Cancer: Targets and Therapy 12, pages 93-102.
Read now
Read now
Louis Gautier. (2021) Past, Present and Future Oncology: Welcome to Volume 17. Future Oncology 17:1, pages 1-5.
Read now
Read now
Articles from other publishers (37)
Michael Menzel, Martina Kirchner, Klaus Kluck, Markus Ball, Susanne Beck, Michael Allgäuer, Christin Assmann, Johannes Schnorbach, Anna‐Lena Volckmar, Timothy Kwang Yong Tay, Hannah Goldschmid, Daniel SW Tan, Michael Thomas, Daniel Kazdal, Jan Budczies, Albrecht Stenzinger & Petros Christopoulos. (2024)
Genomic heterogeneity at baseline is associated with
T790M
resistance mutations in
EGFR
‐mutated lung cancer treated with the first‐/second‐generation tyrosine kinase inhibitors
. The Journal of Pathology: Clinical Research 10:2.
Crossref
Crossref
Jiameng Lu, Xiaoqing Ji, Xinyi Liu, Yunxiu Jiang, Gang Li, Ping Fang, Wei Li, Anli Zuo, Zihan Guo, Shuran Yang, Yanbo Ji & Degan Lu. (2024) Machine learning-based radiomics strategy for prediction of acquired EGFR T790M mutation following treatment with EGFR-TKI in NSCLC. Scientific Reports 14:1.
Crossref
Crossref
Taeyun Kim, Tae Won Jang, Chang Min Choi, Mi-Hyun Kim, Sung Yong Lee, Yoon Soo Chang, Kye Young Lee, Seung Joon Kim, Sei Hoon Yang, Jeong Seon Ryu, Jeong Eun Lee, Shin Yup Lee, Chan Kwon Park, Sang Hoon Lee, Seung Hun Jang, Seong Hoon Yoon & Hyung-Joo Oh. (2023) Final Report on Real-World Effectiveness of Sequential Afatinib and Osimertinib in EGFR-Positive Advanced Non–Small Cell Lung Cancer: Updated Analysis of the RESET Study. Cancer Research and Treatment 55:4, pages 1152-1170.
Crossref
Crossref
Ping-Chih Hsu, Chun-Yao Huang, Yu-Ching Lin, Suey-Haur Lee, Li-Chung Chiu, Chiao-En Wu, Scott Chih-Hsi Kuo, Jia-Shiuan Ju, Allen Chung-Cheng Huang, Ho-Wen Ko, Chin-Chou Wang & Cheng-Ta Yang. (2023) Sequential treatment in advanced epidermal growth factor receptor-mutated lung adenocarcinoma patients receiving first-line bevacizumab combined with 1st/2nd-generation EGFR-tyrosine kinase inhibitors. Frontiers in Oncology 13.
Crossref
Crossref
Si-Yang Maggie Liu, Xiao-Rong Dong, Zhen Wang, Yingying Du, Jiu-Wei Cui, Qian Chu, Bing-Fei Xu, Ming-Ying Zheng, Jia-Yi Deng, Chang Lu, Xue-Wu Wei, Yang-Si Li, Mei-Mei Zheng, Ming-Yi Yang, Jie Huang, Anna Li, Xiao-Yan Bai, Yue-Li Sun, Chong-Rui Xu, Bin-Chao Wang, Hua-Jun Chen, Jin-Ji Yang, Hong-Hong Yan, Wen-Zhao Zhong, Qing Zhou & Yi-Long Wu. (2023) Efficacy, safety and dose selection of AZD3759 in patients with untreated EGFR-mutated non-small-cell lung cancer and central nervous system metastases in China (CTONG1702-Arm 8): a multi-center, single-arm, phase 2 trial. eClinicalMedicine 64, pages 102238.
Crossref
Crossref
Tomoki Hori, Kazuhiro Yamamoto, Takefumi Ito, Shigeki Ikushima, Tomohiro Omura & Ikuko Yano. (2023) Upfront Use of First-/Second-Generation EGFR-TKI Followed by Osimertinib Shows Better Prognosis than Upfront Osimertinib Therapy in Japanese Patients with Non-small-cell Lung Cancer with Exon 19 Deletion: A Single-Center Retrospective Study. Biological and Pharmaceutical Bulletin 46:6, pages 788-795.
Crossref
Crossref
Giulia Corrao, Matteo Franchi, Mattia Zaffaroni, Maria Giulia Vincini, Filippo de Marinis, Lorenzo Spaggiari, Roberto Orecchia, Giulia Marvaso & Barbara Alicja Jereczek-Fossa. (2023) Upfront Advanced Radiotherapy and New Drugs for NSCLC Patients with Synchronous Brain Metastases: Is the Juice Worth the Squeeze? A Real-World Analysis from Lombardy, Italy. Cancers 15:4, pages 1103.
Crossref
Crossref
Julian A. Marin-Acevedo, Bruna Pellini, ErinMarie O. Kimbrough, J. Kevin Hicks & Alberto Chiappori. (2023) Treatment Strategies for Non-Small Cell Lung Cancer with Common EGFR Mutations: A Review of the History of EGFR TKIs Approval and Emerging Data. Cancers 15:3, pages 629.
Crossref
Crossref
Jang Ho Lee, Eun Young Kim, Cheol-Kyu Park, Shin Yup Lee, Min ki Lee, Seong-Hoon Yoon, Jeong Eun Lee, Sang Hoon Lee, Seung Joon Kim, Sung Yong Lee, Jun Hyeok Lim, Tae-Won Jang, Seung Hun Jang, Kye Young Lee, Seung Hyeun Lee, Sei Hoon Yang, Dong Won Park, Chan Kwon Park, Hye Seon Kang, Chang Dong Yeo, Chang-Min Choi & Jae Cheol Lee. (2023) Real-World Study of Osimertinib in Korean Patients with Epidermal Growth Factor Receptor T790M Mutation–Positive Non–Small Cell Lung Cancer. Cancer Research and Treatment 55:1, pages 112-122.
Crossref
Crossref
Saori Takata, Kei Morikawa, Hisashi Tanaka, Hidetoshi Itani, Masashi Ishihara, Kazuya Horiuchi, Yasuhiro Kato, Shinnosuke Ikemura, Hideyuki Nakagawa, Yoshiro Nakahara, Yoshitaka Seki, Akihiro Bessho, Nobumasa Takahashi, Kentaro Hayashi, Takeo Endo, Kiyoshi Takeyama, Toshiya Maekura, Nagio Takigawa, Akikazu Kawase, Makoto Endoh, Kenji Nemoto, Kazuma Kishi, Kenzo Soejima, Yusuke Okuma, Kenichi Yoshimura, Daisuke Saigusa, Yae Kanai, Koji Ueda, Akira Togashi, Noriyuki Matsutani & Nobuhiko Seki. (2023)
Prospective exosome-focused translational research for afatinib (EXTRA) study of patients with nonsmall cell lung cancer harboring
EGFR
mutation: an observational clinical study
. Therapeutic Advances in Medical Oncology 15, pages 175883592311770.
Crossref
Crossref
Wolfgang M. Brueckl, Martin Reck, Harald Schäfer, Kai Neben, Frank Griesinger, Justyna Rawluk, Stefan Krüger, Konrad Kokowski, Joachim H. Ficker, Miriam Möller, Andrea Schueler & Eckart Laack. (2023) Older patients with EGFR mutation-positive non-small cell lung cancer treated with afatinib in clinical practice: A subset analysis of the non-interventional GIDEON study. Journal of Geriatric Oncology 14:1, pages 101394.
Crossref
Crossref
Ying-Yuan Chen, Po-Lan Su, Wei-Li Huang, Chao-Chun Chang, Yi-Ting Yen, Chien-Chung Lin & Yau-Lin Tseng. (2022) The surgical resection of the primary tumor increases survival in patients with EGFR-mutant advanced non-small cell lung cancer: a tertiary center cohort study. Scientific Reports 12:1.
Crossref
Crossref
Minehiko Inomata, Masahiro Matsumoto, Isami Mizushima, Kana Hayashi, Zenta Seto, Kotaro Tokui, Chihiro Taka, Seisuke Okazawa, Kenta Kambara, Shingo Imanishi, Toshiro Miwa, Ryuji Hayashi, Shoko Matsui & Kazuyuki Tobe. (2022) Impact of sequential therapy with osimertinib on the overall survival in patients with EGFR-mutant non-small cell lung cancer. The Egyptian Journal of Bronchology 16:1.
Crossref
Crossref
Nicolas Girard. (2022) EGFR Tyrosine Kinase Inhibitor Sequencing Revisited: From the Revival of Old Tools to the Integration of New Agents. Journal of Thoracic Oncology 17:9, pages 1067-1069.
Crossref
Crossref
Satoru Miura, Hyun Ae Jung, Shin Yup Lee, Seung Hyeun Lee, Min Ki Lee, Yong Chul Lee, Maximilian J Hochmair, Cheng-Ta Yang, Angela Märten, James Chih-Hsin Yang & Sanjay Popat. (2022) Sequential Afatinib and Osimertinib in Asian Patients with EGFR Mutation-Positive Non-Small Cell Lung Cancer and Acquired T790M: Combined Analysis of Two Global Non-Interventional Studies. OncoTargets and Therapy Volume 15, pages 873-882.
Crossref
Crossref
Wang Chun Kwok, James Chung Man Ho, Terence Chi Chun Tam, Mary Sau Man Ip & David Chi Leung Lam. (2022)
Survival benefits from afatinib compared with gefitinib and erlotinib among patients with common
EGFR
mutation in first‐line setting
. Thoracic Cancer 13:14, pages 2057-2063.
Crossref
Crossref
Yen-Hsiang Huang, Kuo-Hsuan Hsu, Jeng-Sen Tseng, Tsung-Ying Yang, Kun-Chieh Chen, Kang-Yi Su, Sung-Liang Yu, Jeremy J. W. Chen & Gee-Chen Chang. (2022) The Difference in Clinical Outcomes Between Osimertinib and Afatinib for First-Line Treatment in Patients with Advanced and Recurrent EGFR-Mutant Non-Small Cell Lung Cancer in Taiwan. Targeted Oncology 17:3, pages 295-306.
Crossref
Crossref
Yen-Hsiang Huang, Kuo-Hsuan Hsu, Chun-Shih Chin, Jeng-Sen Tseng, Tsung-Ying Yang, Kun-Chieh Chen, Kang-Yi Su, Sung-Liang Yu, Jeremy J.W. Chen & Gee-Chen Chang. (2022) The Clinical Outcomes of Different First-Line EGFR-TKIs Plus Bevacizumab in Advanced EGFR-Mutant Lung Adenocarcinoma. Cancer Research and Treatment 54:2, pages 434-444.
Crossref
Crossref
Chi‐Hsien Huang, Jia‐Shiuan Ju, Tzu‐Hsuan Chiu, Allen Chung‐Cheng Huang, Pi‐Hung Tung, Chin‐Chou Wang, Chien‐Ying Liu, Fu‐Tsai Chung, Yueh‐Fu Fang, Yi‐Ke Guo, Chih‐Hsi Scott Kuo & Cheng‐Ta Yang. (2021) Afatinib treatment in a large real‐world cohort of nonsmall cell lung cancer patients with common and uncommon epidermal growth factor receptor mutation. International Journal of Cancer 150:4, pages 626-635.
Crossref
Crossref
Chiao-En Wu, Ching-Fu Chang, Chen-Yang Huang, Cheng-Ta Yang, Chih-Hsi Kuo, Ping-Chih Hsu & John Chang. (2022) Comparison of Different Tyrosine Kinase Inhibitors for Treatment of Poor Performance Status Patients with EGFR-Mutated Lung Adenocarcinoma. Cancers 14:3, pages 674.
Crossref
Crossref
Ping-Chih Hsu, John Wen-Cheng Chang, Ching-Fu Chang, Chen-Yang Huang, Cheng-Ta Yang, Chih-Hsi Scott Kuo, Yueh-Fu Fang & Chiao-En Wu. (2022) Sequential treatment in advanced non–small cell lung cancer harboring EGFR mutations. Therapeutic Advances in Respiratory Disease 16, pages 175346662211327.
Crossref
Crossref
Chia-Ling Li, Te-Chun Hsia, Su-Tso Yang, Kun-San Clifford Chao, Chih-Yen Tu, Hung-Jen Chen & Chia-Hsiang Li. (2022)
Efficacy of Prophylactic Traditional Chinese Medicine on Skin Toxicity of Afatinib in
EGFR
Mutation-Positive Advanced Lung Adenocarcinoma: A Single-Center, Prospective, Double-Blinded, Randomized-Controlled Pilot Trial
. Integrative Cancer Therapies 21, pages 153473542210866.
Crossref
Crossref
Rong Liu, Jianying Zhou & Xia Ling. (2022)
Optimizing Patient Outcomes Through Sequential EGFR TKI Treatment in Asian Patients With
EGFR
Mutation-Positive NSCLC
. Clinical Medicine Insights: Oncology 16, pages 117955492211032.
Crossref
Crossref
Sara Agraso, Martin Lázaro, Xose Luis Firvida, Lucía Santomé, Natalia Fernández, Cristina Azpitarte, Luis Leon, Carme Garcia, Gerardo Hudobro, Ma Carmen Areses, Begoña Campos, Nazaret Quiroga, Jorge García & Joaquín Casal. (2022) Real-world data with afatinib in Spanish patients with treatment-naïve non-small-cell lung cancer harboring exon 19 deletions in epidermal growth factor receptor (Del19 EGFR): Clinical experience of the Galician Lung Cancer Group. Cancer Treatment and Research Communications 33, pages 100646.
Crossref
Crossref
Hai-Yan Tu, Jifeng Feng, Meiqi Shi, Jun Zhao, Yuyan Wang, Jianhua Chang, Jialei Wang, Ying Cheng, Jing Zhu, Eng-Huat Tan, Kai Li, Yiping Zhang, Victor Lee, Cheng-Ta Yang, Wu-Chou Su, David Chi-Leung Lam, B. J. Srinivasa, Senthil Rajappa, Ching-Liang Ho, Kwok Chi Lam, Yi Hu, Shailesh Arjun Bondarde, Xiaoqing Liu, Yahui Tian, Zhiyi Xue, Agnieszka Cseh, Dennis Chin-Lun Huang, Caicun Zhou & Yi-Long Wu. (2022) A Phase IIIb Open-Label, Single-Arm Study of Afatinib in EGFR TKI-Naïve Patients with EGFRm+ NSCLC: Final Analysis, with a Focus on Patients Enrolled at Sites in China. Targeted Oncology 17:1, pages 1-13.
Crossref
Crossref
Sanjay Popat, Hyun Ae Jung, Shin Yup Lee, Maximilian J. Hochmair, Seung Hyeun Lee, Carles Escriu, Min Ki Lee, Maria R. Migliorino, Yong Chul Lee, Nicolas Girard, Hasan Daoud, Angela Märten & Satoru Miura. (2021) Sequential afatinib and osimertinib in patients with EGFR mutation-positive NSCLC and acquired T790M: A global non-interventional study (UpSwinG). Lung Cancer 162, pages 9-15.
Crossref
Crossref
Rintaro Noro, Satoshi Igawa, Akihiro Bessho, Takashi Hirose, Tsuneo Shimokawa, Masanao Nakashima, Koichi Minato, Nobuhiko Seki, Takaaki Tokito, Toshiyuki Harada, Shinji Sasada, Shingo Miyamoto, Yosuke Tanaka, Naoki Furuya, Takayuki Kaburagi, Hideki Hayashi, Hirotoshi Iihara, Hiroaki Okamoto & Kaoru Kubota. (2021) A prospective, phase II trial of monotherapy with low-dose afatinib for patients with EGFR, mutation-positive, non-small cell lung cancer: Thoracic oncology research group 1632. Lung Cancer 161, pages 49-54.
Crossref
Crossref
Jeng-Shiuan Tsai, Po-Lan Su, Szu-Chun Yang, Chao-Chun Chang, Chia-Ying Lin, Yi-Ting Yen, Yau-Lin Tseng, Wu-Wei Lai, Chien-Chung Lin & Wu-Chou Su. (2021) EGFR-TKI plus bevacizumab versus EGFR-TKI monotherapy for patients with EGFR mutation-positive advanced non-small cell lung cancer-A propensity score matching analysis. Journal of the Formosan Medical Association 120:9, pages 1729-1739.
Crossref
Crossref
Valéry Refeno, Michele Lamuraglia, Safae Terrisse, Clément Bonnet, Clément Dumont, Ludovic Doucet, Damien Pouessel & Stephane Culine. (2021) Survival of Patients with Epidermal Growth Factor Receptor-Mutated Metastatic Non-Small Cell Lung Cancer Treated beyond the Second Line in the Tyrosine Kinase Inhibitor Era. Cancers 13:15, pages 3887.
Crossref
Crossref
Donghui Hou, Weihua Li, Sicong Wang, Yao Huang, Jianwei Wang, Wei Tang, Lina Zhou, Linlin Qi, Ning Wu & Shijun Zhao. (2021) Different Clinicopathologic and Computed Tomography Imaging Characteristics of Primary and Acquired EGFR T790M Mutations in Patients with Non-Small-Cell Lung Cancer. Cancer Management and Research Volume 13, pages 6389-6401.
Crossref
Crossref
Yen-Hsiang Huang, Jeng-Sen Tseng, Kuo-Hsuan Hsu, Kun-Chieh Chen, Kang-Yi Su, Sung-Liang Yu, Jeremy J. W. Chen, Tsung-Ying Yang & Gee-Chen Chang. (2021) The impact of different first-line EGFR-TKIs on the clinical outcome of sequential osimertinib treatment in advanced NSCLC with secondary T790M. Scientific Reports 11:1.
Crossref
Crossref
Motohiro Tamiya, Akihiro Tamiya, Norio Okamoto, Yoshihiko Taniguchi, Kazumi Nishino, Shinji Atagi, Tomonori Hirashima, Fumio Imamura, Toru Kumagai & Hidekazu Suzuki. (2021) The ratio of T790M to EGFR-activating mutation predicts response of osimertinib in 1st or 2nd generation EGFR-TKI-refractory NSCLC. Scientific Reports 11:1.
Crossref
Crossref
Hai-Yan Tu, Yang-Si Li, Jin-Ji Yang, Hua-Jun Chen, Ben-Yuan Jiang, Wen-Zhao Zhong, Xue-Ning Yang & Yi-Long Wu. (2021) Long-Term Survival of Over 6 Years with Afatinib Sequential Treatment in a Patient with EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Case Report. Clinical Drug Investigation 41:5, pages 483-488.
Crossref
Crossref
Shun Lu, Jin-Yuan Shih, Tae-Won Jang, Chong-Kin Liam & Yongfeng Yu. (2021) Afatinib as First-Line Treatment in Asian Patients with EGFR Mutation-Positive NSCLC: A Narrative Review of Real-World Evidence. Advances in Therapy 38:5, pages 2038-2053.
Crossref
Crossref
Filippo de Marinis, Konstantin K. Laktionov, Artem Poltoratskiy, Inna Egorova, Maximilian Hochmair, Antonio Passaro, Maria Rita Migliorino, Giulio Metro, Maya Gottfried, Daphne Tsoi, Gyula Ostoros, Simona Rizzato, Guzel Z. Mukhametshina, Michael Schumacher, Silvia Novello, Rafal Dziadziuszko, Wenbo Tang, Laura Clementi, Agnieszka Cseh & Dariusz Kowalski. (2021) Afatinib in EGFR TKI-naïve patients with locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer: Interim analysis of a Phase 3b study. Lung Cancer 152, pages 127-134.
Crossref
Crossref
A.A. Izmailov, A.F. Nasretdinov, A.V. Sultanbaev, D.D. Sakaeva, K.V. Menshikov, N.I. Sultanbaeva & Sh.I. Musin. (2021) The role of second-generation EGFR inhibitors in lung cancer therapy in the realities of modern clinical practice. Onkologiya. Zhurnal imeni P.A.Gertsena 10:4, pages 75.
Crossref
Crossref
Allen Chung-Cheng Huang, Chi-Hsien Huang, Jia-Shiuan Ju, Tzu-Hsuan Chiu, Pi-Hung Tung, Chin-Chou Wang, Chien-Ying Liu, Fu-Tsai Chung, Yueh-Fu Fang, Yi-Ke Guo, Chih-Hsi Scott Kuo & Cheng-Ta Yang. (2021) First- or second-generation epidermal growth factor receptor tyrosine kinase inhibitors in a large, real-world cohort of patients with non-small cell lung cancer. Therapeutic Advances in Medical Oncology 13, pages 175883592110357.
Crossref
Crossref